Clinical trials in Cattolica

In Cattolica, researchers are evaluating a new oral therapy for node‑positive, estrogen receptor‑positive, HER2‑negative early breast cancer that carries a high risk of recurrence. The trial compares this agent with standard endocrine treatment to determine its impact on disease‑free survival.

• Assessment of elacestrant in various combination regimens
• Comparison to conventional endocrine therapy
• Measurement of invasive breast cancer‑free survival as primary endpoint
• Inclusion of both women and men with high‑risk disease

All three studies in the city are actively recruiting, with a team of 53 investigators committed to advancing breast cancer care.

A separate study in Cattolica focuses on elderly patients with advanced NSCLC, exploring whether initiating treatment with durvalumab improves survival compared to starting with standard chemotherapy. Safety, especially early mortality, is a key concern.

• First‑line immunotherapy followed by chemotherapy at progression
• Evaluation of 12‑month overall survival outcomes
• Safety monitoring of death rates within the first four months
• Targeting patients with PDL1 ≥25% or unknown expression

The trial remains open for enrollment, reflecting the city’s active role in oncology research.